{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:29:22Z","timestamp":1786321762627,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92459304"],"award-info":[{"award-number":["92459304"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02771-9","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:02:15Z","timestamp":1786320135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced\/metastatic breast cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"Bo","family":"Lan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faliang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5793-1023","authenticated-orcid":false,"given":"Fuming","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouman","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quchang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"2771_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2771_CR2","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0140-6736(01)06524-2","volume":"358","author":"Collaborative Group on Hormonal Factors in Breast, C","year":"2001","unstructured":"Collaborative Group on Hormonal Factors in Breast, C Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358, 1389\u20131399 (2001).","journal-title":"Lancet"},{"key":"2771_CR3","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.1158\/1078-0432.CCR-16-3227","volume":"23","author":"J Sun","year":"2017","unstructured":"Sun, J. et al. Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients. Clin. Cancer Res. 23, 6113\u20136119 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2771_CR4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"384","author":"C Hu","year":"2021","unstructured":"Hu, C. et al. A population-based study of genes previously implicated in breast cancer. N. Engl. J. Med. 384, 440\u2013451 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2771_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10555-025-10283-1","volume":"44","author":"BA Maiorano","year":"2025","unstructured":"Maiorano, B. A. et al. Hematological toxicity of PARP inhibitors in solid tumors: a systematic review and safety meta-analysis. Cancer Metastasis Rev. 44, 65 (2025).","journal-title":"Cancer Metastasis Rev."},{"key":"2771_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523\u2013533 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2771_CR7","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton, J. K. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N. Engl. J. Med. 379, 753\u2013763 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2771_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1182\/blood-2012-12-472845","volume":"122","author":"J Farres","year":"2013","unstructured":"Farres, J. et al. Parp-2 is required to maintain hematopoiesis following sublethal gamma-irradiation in mice. Blood 122, 44\u201354 (2013).","journal-title":"Blood"},{"key":"2771_CR9","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1634\/theoncologist.2019-0493","volume":"25","author":"SA Hurvitz","year":"2020","unstructured":"Hurvitz, S. A. et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA trial. Oncologist 25, e439\u2013e450 (2020).","journal-title":"Oncologist"},{"key":"2771_CR10","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1001\/jamaoncol.2023.7322","volume":"10","author":"S Morganti","year":"2024","unstructured":"Morganti, S. et al. PARP inhibitors for breast cancer treatment: a review. JAMA Oncol. 10, 658\u2013670 (2024).","journal-title":"JAMA Oncol."},{"key":"2771_CR11","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1101\/gad.334516.119","volume":"34","author":"D Slade","year":"2020","unstructured":"Slade, D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 34, 360\u2013394 (2020).","journal-title":"Genes Dev."},{"key":"2771_CR12","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1158\/1538-7445.AM2021-1632","volume":"11","author":"L Wang","year":"2021","unstructured":"Wang, L. et al. TSL-1502, a glucuronide prodrug of a poly (ADP-ribose) polymerase (PARP) inhibitor, exhibits potent anti-tumor activity in preclinical models. Am. J. Cancer Res. 11, 1632\u20131645 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"2771_CR13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ejmech.2013.12.045","volume":"74","author":"I Tranoy-Opalinski","year":"2014","unstructured":"Tranoy-Opalinski, I. et al. beta-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update. Eur. J. Med. Chem. 74, 302\u2013313 (2014).","journal-title":"Eur. J. Med. Chem."},{"key":"2771_CR14","doi-asserted-by":"publisher","first-page":"7390","DOI":"10.1002\/anie.201916124","volume":"59","author":"MT Jarlstad Olesen","year":"2020","unstructured":"Jarlstad Olesen, M. T., Walther, R., Poier, P. P., Dagn\u00e6s-Hansen, F. & Zelikin, A. N. Molecular, macromolecular, and supramolecular glucuronide prodrugs: lead identified for anticancer prodrug monotherapy. Angew. Chem. Int. Ed. 59, 7390\u20137396 (2020).","journal-title":"Angew. Chem. Int. Ed."},{"key":"2771_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdz012","volume":"30","author":"ME Robson","year":"2019","unstructured":"Robson, M. E. et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann. Oncol. 30, 558\u2013566 (2019).","journal-title":"Ann. Oncol."},{"key":"2771_CR16","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman, B. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J. Clin. Oncol. 33, 244\u2013250 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2771_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2017.09.009","volume":"118","author":"SK Sharma","year":"2017","unstructured":"Sharma, S. K. & Bagshawe, K. D. Antibody directed enzyme prodrug therapy (ADEPT): trials and tribulations. Adv. Drug Deliv. Rev. 118, 2\u20137 (2017).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2771_CR18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.jconrel.2022.07.031","volume":"349","author":"PA Burnouf","year":"2022","unstructured":"Burnouf, P. A., Roffler, S. R., Wu, C. C. & Su, Y. C. Glucuronides: from biological waste to bio-nanomedical applications. J. Control Release 349, 765\u2013782 (2022).","journal-title":"J. Control Release"},{"key":"2771_CR19","doi-asserted-by":"publisher","first-page":"100049","DOI":"10.1016\/j.modpat.2022.100049","volume":"36","author":"KD Doig","year":"2023","unstructured":"Doig, K. D., Fellowes, A. P. & Fox, S. B. Homologous recombination repair deficiency: an overview for pathologists. Mod. Pathol. 36, 100049 (2023).","journal-title":"Mod. Pathol."},{"key":"2771_CR20","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","volume":"24","author":"A Tutt","year":"2018","unstructured":"Tutt, A. et al. Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat. Med. 24, 628\u2013637 (2018).","journal-title":"Nat. Med."},{"key":"2771_CR21","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli, M. L. et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin. Cancer Res. 22, 3764\u20133773 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2771_CR22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10549-022-06785-z","volume":"197","author":"B Xu","year":"2023","unstructured":"Xu, B. et al. Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study. Breast Cancer Res. Treat. 197, 489\u2013501 (2023).","journal-title":"Breast Cancer Res. Treat."},{"key":"2771_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2165\/00003088-199733010-00003","volume":"33","author":"B Sperker","year":"1997","unstructured":"Sperker, B., Backman, J. T. & Kroemer, H. K. The role of beta-glucuronidase in drug disposition and drug targeting in humans. Clin. Pharmacokinet. 33, 18\u201331 (1997).","journal-title":"Clin. Pharmacokinet."},{"key":"2771_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00402-y","volume":"7","author":"L Li","year":"2023","unstructured":"Li, L. et al. HRD effects on first-line adjuvant chemotherapy and PARPi maintenance therapy in Chinese ovarian cancer patients. NPJ Precis. Oncol. 7, 51 (2023).","journal-title":"NPJ Precis. Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02771-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02771-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02771-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:02:16Z","timestamp":1786320136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02771-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2771"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02771-9","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"14 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All patients provided written informed consent before enrollment. The study protocol was approved by the Ethics Committee of the National Cancer Center\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (Approval No. 21\/540-3211). This study was carried out in accordance with the Good Clinical Practice Guidelines, the Declaration of Helsinki, and relevant local laws and regulations. This study is registered with ClinicalTrials.gov (number NCT05420779).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"316"}}